How do you stratify your patients with known ASCVD to determine their eligibility for PCSK9 inhibitors, and are there some patients that you would characterize as ultra-high risk and, therefore, requiring LDL-C lowering to less than 70 mg/dL?

Name: How do you stratify your patients with known ASCVD to determine their eligibility for PCSK9 inhibitors, and are there some patients that you would characterize as ultra-high risk and, therefore, requiring LDL-C lowering to less than 70 mg/dL?
Uploaded: 2019-03-11T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

Matthew Roe, MD

Professor of Medicine
Duke Clinical Research Institute
Duke University School of Medicine
Durham, NC